[go: up one dir, main page]

PL2739268T3 - Sposób i formulacja do inhalacji - Google Patents

Sposób i formulacja do inhalacji

Info

Publication number
PL2739268T3
PL2739268T3 PL11870462T PL11870462T PL2739268T3 PL 2739268 T3 PL2739268 T3 PL 2739268T3 PL 11870462 T PL11870462 T PL 11870462T PL 11870462 T PL11870462 T PL 11870462T PL 2739268 T3 PL2739268 T3 PL 2739268T3
Authority
PL
Poland
Prior art keywords
formulation
inhalation method
inhalation
Prior art date
Application number
PL11870462T
Other languages
English (en)
Inventor
Michelle Mcintosh
David Morton
Tomas SOU
Livesey OLERILE
Richard PRANKERD
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903049A external-priority patent/AU2011903049A0/en
Application filed by Monash University filed Critical Monash University
Publication of PL2739268T3 publication Critical patent/PL2739268T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
PL11870462T 2011-08-01 2011-11-07 Sposób i formulacja do inhalacji PL2739268T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011903049A AU2011903049A0 (en) 2011-08-01 Method and formulation for inhalation
PCT/AU2011/001430 WO2013016754A1 (en) 2011-08-01 2011-11-07 Method and formulation for inhalation
EP11870462.6A EP2739268B1 (en) 2011-08-01 2011-11-07 Method and formulation for inhalation

Publications (1)

Publication Number Publication Date
PL2739268T3 true PL2739268T3 (pl) 2019-07-31

Family

ID=47628537

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11870462T PL2739268T3 (pl) 2011-08-01 2011-11-07 Sposób i formulacja do inhalacji

Country Status (21)

Country Link
US (3) US20140294969A1 (pl)
EP (1) EP2739268B1 (pl)
CN (1) CN103841960B (pl)
AU (1) AU2011374218B2 (pl)
BR (1) BR112014002646B1 (pl)
CA (1) CA2879317C (pl)
CY (1) CY1121373T1 (pl)
DK (1) DK2739268T3 (pl)
ES (1) ES2708218T3 (pl)
HR (1) HRP20190080T1 (pl)
HU (1) HUE041858T2 (pl)
LT (1) LT2739268T (pl)
MX (1) MX355833B (pl)
PL (1) PL2739268T3 (pl)
PT (1) PT2739268T (pl)
RS (1) RS58456B1 (pl)
SI (1) SI2739268T1 (pl)
SM (1) SMT201900058T1 (pl)
TR (1) TR201900670T4 (pl)
WO (1) WO2013016754A1 (pl)
ZA (1) ZA201401526B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
DE602005024413D1 (de) 2004-08-20 2010-12-09 Mannkind Corp Katalyse der diketopiperazinsynthese
EP2322180B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Diketopiperazine salts for drug delivery
CN102614131A (zh) 2005-09-14 2012-08-01 曼金德公司 以提高结晶微粒表面对活性试剂的亲和力为基础的药物配制方法
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
IL313823A (en) 2008-06-13 2024-08-01 Mannkind Corp A dry powder inhaler and system for drug delivery
AU2009259883B2 (en) 2008-06-20 2015-02-05 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
KR20130117755A (ko) 2010-06-21 2013-10-28 맨카인드 코포레이션 건조 분말 약물 운반 시스템 및 방법
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX355833B (es) * 2011-08-01 2018-05-02 Univ Monash Metodo y formulacion para inhalacion.
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
BR112015000529B1 (pt) 2012-07-12 2022-01-11 Mannkind Corporation Inalador de pó seco
BR112016000937A8 (pt) * 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
WO2015175961A1 (en) * 2014-05-16 2015-11-19 Stc.Unm Vaccination compositions, methods of making, and methods of use
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
US11589603B2 (en) 2015-09-11 2023-02-28 Abbott Laboratories Powdered nutritional product containing branched-chain amino acids and a sugar alcohol
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
PT108885B (pt) 2015-10-12 2019-02-13 Hovione Farm S A Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos
EA201991096A1 (ru) 2016-10-31 2019-09-30 Вектура Лимитед Ингалируемая порошковая композиция, содержащая анти-il-13-антитело
CA3048677A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
CN111202722A (zh) * 2020-02-13 2020-05-29 江苏艾立康药业股份有限公司 一种洛匹那韦吸入干粉药物组合物及其制备方法
CN111202723A (zh) * 2020-02-15 2020-05-29 江苏艾立康药业股份有限公司 一种达芦那韦吸入干粉药物组合物及其制备方法
CN111202724A (zh) * 2020-02-16 2020-05-29 江苏艾立康药业股份有限公司 一种阿比朵尔吸入干粉药物组合物及其制备方法
WO2021247850A2 (en) 2020-06-05 2021-12-09 Cook Medical Technologies Llc Medical scopes for delivering therapeutic agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6749835B1 (en) * 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0304540D0 (en) * 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
US20050186146A1 (en) * 2004-02-12 2005-08-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
CA2616778A1 (en) * 2005-07-27 2007-02-01 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
CN101888831A (zh) * 2007-10-05 2010-11-17 哈佛大学的校长及成员们 细胞材料的干粉
WO2009143011A1 (en) * 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
CN101669925B (zh) * 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
MX355833B (es) * 2011-08-01 2018-05-02 Univ Monash Metodo y formulacion para inhalacion.

Also Published As

Publication number Publication date
EP2739268A4 (en) 2015-03-25
EP2739268A1 (en) 2014-06-11
US12186361B2 (en) 2025-01-07
SI2739268T1 (sl) 2019-05-31
CA2879317C (en) 2019-01-15
BR112014002646A8 (pt) 2017-06-20
ZA201401526B (en) 2017-09-27
LT2739268T (lt) 2019-03-25
CN103841960A (zh) 2014-06-04
EP2739268B1 (en) 2018-10-31
CN103841960B (zh) 2017-07-07
US20220152145A1 (en) 2022-05-19
US20170224762A1 (en) 2017-08-10
US20140294969A1 (en) 2014-10-02
ES2708218T3 (es) 2019-04-09
SMT201900058T1 (it) 2019-02-28
HRP20190080T1 (hr) 2019-03-22
MX2014001345A (es) 2014-11-13
BR112014002646B1 (pt) 2021-09-14
US11065297B2 (en) 2021-07-20
PT2739268T (pt) 2019-01-28
HUE041858T2 (hu) 2019-05-28
BR112014002646A2 (pt) 2017-06-13
AU2011374218B2 (en) 2017-05-11
CA2879317A1 (en) 2013-02-07
MX355833B (es) 2018-05-02
AU2011374218A1 (en) 2014-03-20
CY1121373T1 (el) 2020-05-29
WO2013016754A1 (en) 2013-02-07
TR201900670T4 (tr) 2019-02-21
DK2739268T3 (en) 2019-02-25
RS58456B1 (sr) 2019-04-30

Similar Documents

Publication Publication Date Title
HRP20190080T1 (hr) Postupak i formulacija za inhaliranje
HK1177005A1 (zh) 附屬設備及其方法
BR112014000238A2 (pt) método e artigo
EP2755720A4 (en) SYSTEMS AND METHODS FOR THE THERAPY OF SLEEP APNEA
BR112013017254A2 (pt) equipamento e método implantado por computador
HK1199694A1 (zh) 益生菌組合物和方法
BR112014010450A2 (pt) composição e método
BR112013014644A2 (pt) composição farmacêutica e complexo
BR112013022766A2 (pt) método de administração de d-pirfenidona e kit
BR112014000015A2 (pt) formulação
SMT201600465B (it) Dispositivo di inalazione
BR112013022306A2 (pt) método, e, composição
IT1403906B1 (it) Apparato e metodo per realizzare sbozzati
IL231094A0 (en) Fish anesthetic and method
IL227649A0 (en) Insecticidal composition and processes related thereto
BR112014010860A2 (pt) composição e método
EP2770828A4 (en) FORMULATION
BR112013019224A2 (pt) composição, e metodo
IL231496A0 (en) Hybrid gaming system and method
IL231798A0 (en) Method and composition
BR112013022530A2 (pt) método terapêutico homeopático e composições
PL2678714T3 (pl) Dozymetr zdarzeń i powiązane sposoby
BR112014010152A2 (pt) formulação esporicida e lenço
FI20115244A0 (fi) Menetelmä ja järjestely
FI20115100A0 (fi) Pinnoitusmenetelmä ja -järjestely